
We will promptly coordinate a doctor consultation and medical treatment in Israel.
Tel / Whatsapp / Viber +972 54 803 45 32 info@resultmed.com
!מבקרים באתר היקרים, אנא שימו לב
.אנחנו חברה תיירות מרפא. אנו נותנים שרות פרטי לתיירים בלבד
FDA approved under an accelerated program using Atezolizumab (Tecentriq) and Nab-Paclitaxel (a combination of immunotherapy with chemotherapy). This combination, as the first-line treatment, increases the overall survival in patients with triple negative breast cancer (TNBC). In fact, it is the first immunotherapy approved for this diagnosis.
Results of the Impassion130 study were presented at the conference of the European Society of Medical Oncology (ESMO) and the Меdical Journal of New England. 902 patients took part in this study.
Women were divided into two groups equally by 451 persons. All the women were previously diagnosed with advanced or metastatic triple negative breast cancer. Atezolizumab with Nab-Paclitaxel or placebo with Nab-Paclitaxel were prescribed to them.
Doctors for Breast Cancer – Get a Second Opinion
Survival in groups with immunotherapy, and with standard treatment:
In subgroups with positive PD-L1, or with increased expression of immune cells equal to or greater than 1%:
It was notes reduction in mortality risk as well as an increase in survival in the immunotherapy group compared with standard treatment:
During the study, the disease was diagnosed or progressed:
The most common adverse events noted by researchers:
Adverse events were recorded in both groups, while no new problems were noticed in the immunotherapy group.
Source: E-med, Israel.
!מבקרים באתר היקרים, אנא שימו לב
.אנחנו חברה תיירות מרפא. אנו נותנים שרות פרטי לתיירים בלבד